Clinical Trial

Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini

Study acronym: ADORA-VI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to assess the efficacy, safety and acceptability of ascending doses of arpraziquantel in children infected with Opisthorchis viverrini. The primary objective is to determine the dose-response relationship in terms of cure rate. This study will involve children aged 6-7 years, since O. viverrini infections often occur in pre-school and school-aged children, and this group is largely left untreated in current public health programs.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-05
notable Primary completion pushed: 2026-08 -> 2026-10 2026-07-15
minor Completion pushed: 2026-08 -> 2026-10 2026-07-15
Trial Details
NCT Number NCT07262814
Lead Sponsor Jennifer Keiser
Collaborators: Lao Tropical and Public Health Institute
Conditions Opisthorchis Viverrini
Enrollment 125 participants
Start Date 2026-07-22
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-04